Evoq Remedies Complete Financial Statements
In FYNone, Evoq Remedies (EVOQ) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00. Full financial statements from FY2019 to FY2025 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see EVOQ stock price BSE.
7 Years of Data
2025 - 2019
Complete Financial Data Export
Profitability Ratios
Operating Margin
-19.00%
2025 data
Balance Sheet Ratios
Equity Ratio
90.00%
2025 data
Asset Turnover
0.28
2025 data
EVOQ Revenue, Net Profit & EBITDA — Year-on-Year Growth
EVOQ YoY (March 2025 vs Period) — revenue -100.0%, expenses -100.0%.
Revenue Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+35.1%
Year-over-Year
Equity Growth
+80.0%
Year-over-Year
Operating Cash Flow Growth
-400.0%
Year-over-Year
Financing Cash Flow Growth
+400.0%
Year-over-Year
EVOQ Income Statement — Revenue, EBITDA & Net Profit
Evoq Remedies revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None). Explore EVOQ fundamental worth to estimate fundamental worth using multiple valuation models.
Periods
₹ Crores
| Particulars | None | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 14 | 6 | 26 | 17 | 10 | 9 | 3 |
| Expenses | 0 | 14 | 6 | 24 | 15 | 9 | 9 | 3 |
| EBITDA | 0 | 0 | 1 | 2 | 2 | 1 | 0 | 0 |
| Operating Profit Margin % | 0.00% | -19.00% | -40.00% | -18.00% | 9.00% | 10.00% | 0.00% | 1.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 1 | 2 | 2 | 1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
| Earnings Per Share (₹) | 0.00 | 0.04 | 0.33 | 1.19 | 0.70 | 715.00 | 0.00 | 0.16 |
EVOQ Balance Sheet — Assets, Liabilities & Shareholders' Equity
EVOQ total assets ₹50 Cr, total equity ₹45 Cr, total liabilities ₹ Cr (2025).
Years
Annual Data
₹ Crores
| Particulars | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Total Assets | 50 | 37 | 35 | 33 | 8 | 6 | 2 |
| Current Assets | 50 | 37 | 35 | 33 | 8 | 6 | 2 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Work in Progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 50 | 37 | 35 | 33 | 8 | 6 | 2 |
| LIABILITIES | |||||||
| Total Liabilities | |||||||
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | |||||||
| SHAREHOLDERS' EQUITY | |||||||
| Total Equity | 45 | 25 | 25 | 23 | 1 | 0 | 0 |
| Share Capital | 25 | 14 | 14 | 14 | 0 | 0 | 0 |
| Reserves & Surplus | 20 | 12 | 11 | 10 | 1 | 0 | 0 |
EVOQ Cash Flow Statement — Operating, Investing & Financing
Evoq Remedies operating cash flow ₹-15 Cr, investing ₹0 Cr, financing ₹15 Cr, net cash flow ₹0 Cr (2025).
Periods
₹ Crores
| Particulars | March 2025 | March 2024 | March 2023 | March 2022 | March 2021 | March 2020 | March 2019 |
|---|---|---|---|---|---|---|---|
| Operating Activities | -15 | 5 | -4 | -26 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Activities | 15 | -5 | 1 | 30 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | -3 | 3 | 0 | 0 | 0 |